MicroOmix
MicroOmix (founded 2020, Illkirch-Graffenstaden, France) develops microfluidic-based single-cell secretion analysis technology, partnering with pharmaceutical, cell therapy, and biotech companies to discover and recover rare high-secreting cell sub-populations for antibody discovery, regenerative medicine, and CAR T cell optimization.
- Company typePrivate
- Founded2020
- HeadquartersIllkirch-graffenstaden, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What MicroOmix does
MicroOmix is a French biotechnology startup founded in 2020 and headquartered in Illkirch-Graffenstaden (Strasbourg metropolitan area). The company develops microfluidic-based technologies that transform the surface of picoliter-size droplets into highly sensitive sensors, enabling the analysis of secreted proteins at the single-cell level with sensitivity down to 10-21 mole. Its core technology resolves rare sub-populations at a 1/10,000 ratio and can recover and re-expand selected cells for further analysis, with cells maintainable alive within droplets for up to four days for signature biomarker detection. The IP foundation is grounded in work from CNRS laboratories and the University of Strasbourg: co-founders Dr. Alain Wagner (director, Bio-Functional Chemistry team, UMR 7199) and Pr Michaël Ryckelynck (group leader, Digital Biology of RNA team, UPR 9002 at CNRS-IBMC), with the platform protected by European Patent N° 16,305,394.5 and PCT/EP/2017/058035, and capture/inversion technologies licensed-in from bioMérieux.
The company monetizes the platform primarily through biotherapeutics discovery collaborations with pharmaceutical and biotechnology partners, structured as co-development programs from target to lead biotherapeutics on an FTE plus success-fee basis (live since 2023). A second go-to-market motion is planned around bench-top instruments and consumables sold to established markets with large user bases, targeting recurrent cell screening needs such as antibody-secreting hybridomas and cell line development. Headquartered team is five core members led by CEO Christophe Arnaud, a Centrale Paris/UPC engineer with prior industrial experience at Rhone-Poulenc, L'Oréal, and Elis, and 17 years of founder/manager experience at Emulsar.
MicroOmix serves pharmaceutical companies developing next-generation antibody therapeutics (notably anti-GPCR monoclonals), cell therapy developers optimizing CAR T cell performance, regenerative medicine companies requiring secretion-based differentiated cell enrichment, and biotechnology companies engaged in biologics discovery. Founding support comes from Conectus, Semia, Region Grand Est, CNRS, University of Strasbourg, ITI IMS, ITI IMCBio+, and LabEx netrna. Channels are direct enterprise: a dedicated biotherapeutics contact email and the corporate website serve as the primary B2B engagement surface, with no app, public API, SDK, or disclosed named customer contracts.
MicroOmix firmographics
Firmographics- Name
- MicroOmix
- Legal name
- MicroOMix
- Website
- https://microomixtech.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MicroOmix (founded 2020, Illkirch-Graffenstaden, France) develops microfluidic-based single-cell secretion analysis technology, partnering with pharmaceutical, cell therapy, and biotech companies to discover and recover rare high-secreting cell sub-populations for antibody discovery, regenerative medicine, and CAR T cell optimization.
- Ownership category
- akta.pro rank
MicroOmix industry classification
Industry- Product category
- Microfluidic Biotherapeutics Discovery Technology
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
- akta.pro secondary industries
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where MicroOmix is headquartered
LocationHeadquarters
- HQ city
- Illkirch-graffenstaden
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
MicroOmix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biotherapeutics Discovery Collaborations: Development collaborations with pharmaceutical and biotech companies from target to lead biotherapeutics, generating revenue through FTE plus success fees
- Instrument and Consumables Sales: Bench-top instrument and consumables sales targeting established, large user markets with standard conditions and recurrent needs
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
MicroOmix product offering
Product offeringCore offering
MicroOmix develops and applies a proprietary microfluidic-based technology platform that transforms picoliter-size droplet surfaces into highly sensitive sensors for analyzing proteins secreted by individual cells, achieving sensitivity down to 10-21 mole and rare sub-population resolution of 1/10,000. The company monetizes this platform today through biotherapeutics discovery collaborations with pharmaceutical and biotechnology companies (target-to-lead co-development, FTE and success fees) and application-specific services in antibody discovery, CAR T cell optimization, and regenerative medicine. It also plans to sell bench-top microfluidic instruments and consumables for established cell-screening operations.
Product overview
MicroOmix offers a microfluidic-based technology platform for analyzing secreted proteins at the single-cell level. The core MicroOmiX Microfluidic Technology Platform transforms picoliter-size droplets into highly sensitive sensors for detecting secreted biomarkers. The platform supports multiple application services including Antibody Discovery Service, Secretion-Based Cell Selection (for antibody development, regenerative medicine, CAR T cell optimization, and enzymatic activity sorting), and Biotherapeutics Discovery Programs through co-development collaborations. Additionally, the company offers Bench-Top Instruments and Consumables for recurrent cell screening operations. The technology is protected by European Patent N° 16,305,394.5 and PCT/EP/2017/058035.
Differentiator
Problem solved
Functional benefit
Products and services
- Biotherapeutics Discovery Programs Tailor-made co-development collaboration programs from target to lead biotherapeutics, enabling screening of large numbers of cells with high assay relevance and readout resolution for pharmaceutical and biotechnology partners; revenue is generated through an FTE plus success fees model starting in 2023.
- Antibody Discovery Service Service applying the MicroOmiX microfluidic platform to antibody development through secretion-phenotype based screening, enabling sorting by affinity, selectivity, or quantity and detection of signature biomarkers from cells kept alive in droplets for up to four days.
- Secretion-Based Cell Selection Service Tailored service using a two-component molecular system and bio-orthogonal chemical reaction for applications including secretion-phenotype based antibody development (e.g. Anti-GPCR mAb), differentiated cell enrichment for regenerative medicine, CAR T cell performance optimization, and secreted enzymatic activity-based cell sorting.
- Bench-Top Microfluidic Instrument and Consumables Planned bench-top instrument and consumables product line providing speed and higher performance on established recurrent needs, standard conditions, and large user market applications in cell screening operations including antibody-secreting hybridomas and cell line development.
Quantifiable outcome
- Sensitivity down to 10-21 mole (zeptomole)
- +2 more outcomes
Companies that use MicroOmix
Customer profileSegments4 records
Ideal customer profiles3 records
MicroOmix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
MicroOmix partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- CNRS (Bio-Functional Chemistry team/BFC)coreDr. Alain Wagner directs the BFC (Bio-Functional Chemistry) team - UMR 7199 at University of Strasbourg. Core academic research partner providing intellectual property and research infrastructure.
- University of StrasbourgcoreAcademic research institution providing laboratory space, research infrastructure, and talent through CNRS-affiliated researchers including Dr. Wagner, Pr Ryckelynck, and team members.
- ITI IMS (Imaging Multi-Modality for Sciences)minorInterdisciplinary Thematic Institute focused on imaging technologies. Listed as founding partner.
- ITI IMCBio+minorInterdisciplinary Thematic Institute focused on integrative molecular and cellular biology. Listed as founding partner.
- LabEx netrnaminorExcellence laboratory focused on RNA biology. Listed as founding partner.
- ARN (Digital Biology of RNA team)corePr Michaël Ryckelynck leads the Digital Biology of RNA team - UPR 9002 at CNRS-IBMC, providing microfluidic expertise and technology development.
- bioMérieuxminorMolecular diagnostics company. Dr. Sylvain Ursuegui completed doctorate in collaboration with bioMérieux; holds two patents with the company that will be exploited by MicroOmiX.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
MicroOmix competitors and assessment
Company assessmentEmerging players
- Cytek Biosciences: High-parameter flow cytometry platform increasingly adopted for immune-cell profiling and cell-therapy QC; emerging alternative in the same single-cell analytics budgets as MicroOmix.
- NanoCellect Biomedical: Microfluidic cell-sorting platform (WOLF) used in antibody discovery and cell-therapy workflows; emerging direct alternative in the niche MicroOmix occupies.
Broad incumbents
- 10x Genomics: Dominant single-cell analysis platform (Chromium, Xenium) widely used in pharma/biotech research; adjacent competitor to MicroOmix for budget allocation in pharma single-cell and antibody-discovery workflows.
- Becton, Dickinson and Company (BD): BD's cell-sorting and flow-cytometry portfolio (FACSAria, BD FACSDiscover) is routinely used in antibody discovery and cell-therapy workflows and represents the incumbent alternative to microfluidic droplet screening.
- Miltenyi Biotec: Offers MACS cell-sorting and analytical flow cytometry, plus cell-therapy manufacturing solutions; competes for the CAR-T and regenerative-medicine workflow budgets MicroOmix targets.
- Berkeley Lights (now part of PhenomeX): Berkeley Lights pioneered functional single-cell screening using opto-fluidic platforms; directly comparable to MicroOmix's single-cell secretion-analysis value proposition for antibody discovery and cell therapy.
- Bruker Cellular Analysis: Acquired PhenomeX; offers Beacon single-cell optofluidic platform for antibody discovery and cell-line development, competing head-on for MicroOmix's pharma biotherapeutics customers.
Direct peers
- Sphere Fluidics: Developer of Cyto-Mine, a droplet microfluidic platform for single-cell antibody-secreting cell screening — the closest direct analog to MicroOmix's droplet-based secretion analysis workflow.
- AbCellera Biologics: AI-powered antibody discovery platform with droplet-based single-cell screening capabilities; competes with MicroOmix for the same anti-GPCR and rare-clone antibody discovery use cases.
- IsoPlexis (now part of standard BioTools): Single-cell functional proteomics (IsoCode/CodePlex) player focused on secretion profiling of T cells and CAR-T cells — overlapping with MicroOmix's CAR-T secretion-based optimization use case.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MicroOmix social profiles
Digital presenceMicroOmix compliance and trust
Trust signalCompliance1 record
MicroOmix financial estimates
Financial estimateRevenue estimate
Valuation estimate
MicroOmix leadership team
Management profileNumber of profiles
Profiles5 records
MicroOmix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MicroOmix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MicroOmix
What does MicroOmix do?
MicroOmix develops and applies a proprietary microfluidic-based technology platform that transforms picoliter-size droplet surfaces into highly sensitive sensors for analyzing proteins secreted by individual cells, achieving sensitivity down to 10-21 mole and rare sub-population resolution of 1/10,000. The company monetizes this platform today through biotherapeutics discovery collaborations with pharmaceutical and biotechnology companies (target-to-lead co-development, FTE and success fees) and application-specific services in antibody discovery, CAR T cell optimization, and regenerative medicine. It also plans to sell bench-top microfluidic instruments and consumables for established cell-screening operations.
Is MicroOmix a public or private company?
MicroOmix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MicroOmix founded?
MicroOmix was founded in 2020. It employs 1 to 10 people.
Where is MicroOmix based?
MicroOmix is headquartered in Illkirch-graffenstaden, France, in the Europe region.
How does MicroOmix make money?
Two revenue lines are on record. Biotherapeutics Discovery Collaborations are the primary driver. The others are instrument and Consumables Sales.
Who are MicroOmix's main competitors?
Emerging players on record are Cytek Biosciences and NanoCellect Biomedical. Broad incumbents are 10x Genomics, Becton, Dickinson and Company (BD), Miltenyi Biotec, Berkeley Lights (now part of PhenomeX) and Bruker Cellular Analysis. Direct peers are Sphere Fluidics, AbCellera Biologics and IsoPlexis (now part of standard BioTools).
Does MicroOmix have an API?
No public API is recorded for MicroOmix.
What industry is MicroOmix in?
MicroOmix's product category is Microfluidic Biotherapeutics Discovery Technology. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.